mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome

Journal of Clinical Oncology

Volumn 29, Issue 6, 2011, Pages

  Klümpen, Heinz Josef ^a   Queiroz, Karla C S ^a   Spek, C Arnold ^a   Van Noesel, Carel J M ^a   Brink, Helmy C ^a   De Leng, Wendy W J ^b   De Wilde, Roeland F ^b   Mathus Vliegen, Elisabeth M H ^a   Offerhaus, G Johan A ^b   Alleman, Maarten A ^c   Westermann, Anneke M ^a   Richel, Dirk J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Isala Klinik   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PROTEIN KINASE LKB1;

ADULT; ANAMNESIS; ARTHRALGIA; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; GENE LOCUS; GENE MUTATION; GENOTYPE; HUMAN; LETTER; MALE; MYALGIA; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PEUTZ-JEGHERS SYNDROME; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79952148073     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.7825     Document Type: Letter

References (15)

1. Jenne DE, Reimann H, Nezu J, et al: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18:38-43, 1998 (Pubitemid 28027876)
2. Hezel AF, Bardeesy N: LKB1: Linking cell structure and tumor suppression. Oncogene 27:6908-6919, 2008
3. van Lier MG, Wagner A, Mathus-Vliegen EM, et al: High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. Am J Gastroenterol 105:1258-1264, 2010
4. Giardiello FM, Brensinger JD, Tersmette AC, et al: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447-1453, 2000 (Pubitemid 32198669)
5. Hardie DG: AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8:774-785, 2007
6. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909, 1991 (Pubitemid 21917235)
7. Shackelford DB, Vasquez DS, Corbeil J, et al: mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A 106:11137-11142, 2009
8. Mahoney CL, Choudhury B, Davies H, et al: LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 100:370-375, 2009
9. Morton JP, Jamieson NB, Karim SA, et al: LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139:586-597, 2010
10. Soria JC, Shepherd FA, Douillard JY, et al: Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 20:1674-1681, 2009
11. Wei C, Amos CI, Zhang N, et al: Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 14:1167-1171, 2008 (Pubitemid 351302565)
12. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al: Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 28:835-840, 2010
13. Katajisto P, Vaahtomeri K, Ekman N, et al: LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet 40:455-459, 2008 (Pubitemid 351450888)
14. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12:9-22, 2007 (Pubitemid 47001784)
15. Vaahtomeri K, Ventelä E, Laajanen K, et al: Lkb1 is required for TGFbeta-mediated myofibroblast differentiation. J Cell Sci 121:3531-3540, 2008